Evidence map›Paper›PMID 37047215›Full record

ReviewInternational journal of molecular sciences2023

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency.

Juan A De Pablo-Moreno, Andrea Miguel-Batuecas, María de Sancha, Antonio Liras

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Antioxidant and Anticoagulant Screening ofCardiovascular & hematological disorders drug targets · 2026
    Article
  4. Proteolytic Profiles ofCurrent pharmaceutical biotechnology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Peptidases: Role and Function in Health and Disease.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Juan A De Pablo-MorenoDepartment of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain.ORCID 0000-0002-9491-5572
Andrea Miguel-BatuecasDepartment of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain.ORCID 0000-0002-0985-2045
María de SanchaDepartment of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain.
Antonio LirasDepartment of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain.
Universidad Complutense de Madrid · ES

Funding

Association for Research and Cure of Factor V deficiency (ASDEFAV) ASDEFAV/2021-23
6 · The paper itself

Abstract

Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.

Indexed as

Factor VFactor V DeficiencyAnticoagulantsBlood CoagulationEndopeptidasesHumansPeptide HydrolasesAnticoagulantsEndopeptidasesFactor VPeptide Hydrolasescoagulationcoagulopathiesequityfactor Vhomeostasisproteasesrare diseases

Identifiers

PMID37047215
PMCPMC10093859
OpenAlexW4361007472

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.